Neumora Therapeutics Faces Class Action Lawsuit Over Misleading Statements - Investors Take Action

Class Action Lawsuit Filed Against Neumora Therapeutics, Inc.

Overview

On March 31, 2025, The Gross Law Firm announced a class action lawsuit against Neumora Therapeutics, Inc. (NASDAQ: NMRA). Investors who acquired shares during a specific period are advised to reach out to the firm to explore options for recovery. The firm emphasizes that one does not need to be appointed as a lead plaintiff to seek recovery.

Class Period and Allegations

This action pertains to shareholders who purchased Neumora's stock around September 15, 2023. The allegations in the lawsuit include claims that Neumora made materially false or misleading statements regarding its Phase Three Program for Navacaprant, its flagship therapeutic candidate aimed at treating Major Depressive Disorder (MDD). Key claims include:

1. Amended Trial Criteria: Neumora allegedly amended the inclusion criteria for its Phase Two clinical trials to include patients with moderate to severe MDD. This amendment may have been necessary to demonstrate significant improvements in treatment outcomes with Navacaprant.

2. Statistical Analysis Adjustments: The lawsuit indicates that the company added a prespecified analysis to the Phase Two statistical analysis plan, specifically targeting moderate to severe cases of MDD. This decision raises eyebrows regarding the integrity of the data presented to investors.

3. Inadequate Data Representation: Concerns have been raised regarding the Phase Two trials, particularly about the quality and adequacy of data. Questions regarding patient population size and sex ratios have emerged, suggesting that the trials could not reliably predict the outcomes of related studies, such as KOASTAL-1.

Action Steps for Shareholders

Potential class members must act quickly, as the deadline to register and apply to be a lead plaintiff is April 7, 2025. Interested shareholders can register through the link provided by The Gross Law Firm. Upon registration, shareholders will benefit from a portfolio monitoring service that provides updates throughout the case's proceedings.

The Role of The Gross Law Firm

The Gross Law Firm is recognized nationally for its class action expertise, working diligently to safeguard investors’ rights against fraudulent activities and unethical business practices. With a mission to ensure corporate accountability, the firm actively pursues recovery for investors impacted by misleading information and inflated stock valuations stemming from corporate misrepresentation.

Conclusion

For investors in Neumora Therapeutics, this lawsuit highlights the importance of vigilance and the need to understand corporate disclosures thoroughly. Those who believe they are affected are strongly encouraged to engage with The Gross Law Firm and explore their rights to potential recovery. This situation also serves as a reminder of the complexities and risks inherent in investing, especially within the biopharmaceutical sector.

For more details or to contact The Gross Law Firm, you can visit their official website or reach out via the provided contact information.

Contact Information for The Gross Law Firm:
15 West 38th Street, 12th Floor
New York, NY 10018
Email: [email protected]
Phone: (646) 453-8903